Source link : https://www.breast-cancers.com/2020/02/14/investigational-subcutaneous-formulation-of-vedolizumab-achieves-clinical-remission-at-week-52-in-patients-with-moderately-to-severely-active-crohns-disease-associated-press/

Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease Associated Press

Source link : https://apnews.com/Business%20Wire/cbe82842b17a4462bd02423133b29132

Author :

Publish date : 2020-02-14 14:55:41

Copyright for syndicated content belongs to the linked Source.

Author : breastcancers

Publish date : 2020-02-14 15:14:08

Copyright for syndicated content belongs to the linked Source.